Shots:

• Voyager to receive $65M upfront and will be responsible for research- IND submission and onset of P-I trial for targets provided by AbbVie. AbbVie to get a WW option to license rights to futher develop and commercialize one or more vectorized alpha-synuclein Abs for Parkinson's and other synucleinopathies
• If AbbVie exercises its option to license- Voyager will receive $245M as P-I option- $1.2B milestones including regulatory & commercial sales and royalties on global sales of products
• Voyager’s technology is an AVV gene therapy technology enabling the development of therapies utilizing blood-brain barrier penetrant AVV capsids in neurological disorders including Parkinson's disease- Alzheimer's disease- Huntington's disease & Friedreich's ataxia

Ref: AbbVie | Image:AbbVie